Evidence record · ER-SEMAGLUTIDE-WEIGHT-012
Does authorised semaglutide medicine produce weight loss?
Authorised semaglutide medicine produces weight loss in eligible adults
Authorised semaglutide medicine produces clinically meaningful weight loss in eligible adults when used with lifestyle support. Large randomised trials and the UK product authorisation support this claim. The result applies to the regulated medicine, population and monitoring pathway, not to unlicensed semaglutide sold as a research vial.
Claim boundary
What this verdict covers
The claim concerns the authorised weight-management medicine in adults who meet the labelled eligibility criteria, alongside reduced-calorie diet and increased physical activity. It does not cover unverified compounded or research products.
- Compound
- Semaglutide
- Population
- Adults with obesity, or overweight with a related condition
- Outcome
- Percentage change in body weight
- Record ID
- ER-SEMAGLUTIDE-WEIGHT-012
Evidence synthesis
What the research can support
In STEP 1, once-weekly semaglutide 2.4 mg produced substantially greater mean weight loss than placebo over 68 weeks in adults without diabetes. The UK SmPC defines the authorised population, contraindications, warnings and monitoring context.
Why the confidence is high
Trial averages do not predict an individual result. Gastrointestinal effects, gallbladder events, pancreatitis warnings and other label risks must remain in the same decision frame as benefit.
Decision boundary
What this record cannot tell you
This record cannot identify the contents, strength, purity, sterility or stability of a particular vial. It does not provide a dosing plan, administration instructions or a personal treatment recommendation. A supported narrow outcome cannot be transferred to a different route, population or product.
This publication has not independently tested a product for this record. Product evidence belongs to a named batch and method; clinical evidence belongs to the intervention actually studied.
From our work: how we checked this claim
ER-SEMAGLUTIDE-WEIGHT-012 addresses one bounded question: Does authorised semaglutide medicine produce weight loss?. Yianni Kiromitis checked the search record, source descriptions, study design, population, intervention identity, comparator and patient-important outcomes against the published evidence method. The source ledger contains 3 primary or official sources. Each was assigned only the proposition it can support; a regulatory document was not treated as a treatment trial, and an animal or laboratory finding was not presented as a dependable human outcome.
The recorded evidence basis is Relevant human, the verdict is Supported and confidence is High. Eleni Kiromitis reviewed study design, biomedical evidence, laboratory context and analytical limits. Dr Stavroula Nikitopoulou reviewed the clinical claim, adverse effects, contraindications, red flags and patient-facing safety wording. Both completed their assigned review on 10 August 2026. Yianni retained publication and correction responsibility. The review notes identify which source supports each material claim and which limitation must remain beside the conclusion.
No direct product testing, seller data, personal treatment experience or patient experience was used to set this verdict. The record cannot establish the contents, strength, purity, sterility or stability of a particular vial, and it does not provide dosing, administration or personalised treatment advice. A finding cannot be transferred to a different route, population, product or outcome without new evidence. We also checked the visible review date against the publication record and structured data. A new controlled study, regulator update, corrected source, analytical report or credible safety signal can trigger reassessment through the public correction route.
Source ledger
Evidence used for this verdict
Each source supports only the proposition stated beside it. Regulatory scope and study scope remain visible.
| Source | What it establishes | What it does not establish | Checked |
|---|---|---|---|
| STEP 1 randomised trial | The large trial found substantially greater weight loss with semaglutide than placebo. | It does not verify unlicensed semaglutide products. | 10 August 2026 |
| Wegovy UK Summary of Product Characteristics | The SmPC defines the authorised product, indication, warnings and use conditions. | It does not apply to a differently made vial. | 10 August 2026 |
| MHRA GLP-1 safety guidance | MHRA sets current safety and misuse context for GLP-1 medicines. | It is not an individual treatment recommendation. | 10 August 2026 |
Quick answers
Frequently asked questions
What is the verdict on Semaglutide for this claim?
The verdict is supported for the precise claim stated on this page. It combines the evidence type, directness, consistency and study limits; it is not a rating of the compound as a whole. The confidence field shows how readily new evidence could change the conclusion.
What evidence supports this verdict?
In STEP 1, once-weekly semaglutide 2.4 mg produced substantially greater mean weight loss than placebo over 68 weeks in adults without diabetes. The UK SmPC defines the authorised population, contraindications, warnings and monitoring context. The source ledger below links the primary or regulatory records used and states what each source cannot establish.
Does this evidence apply to a peptide vial sold online?
No. A study or authorisation applies to the exact material, formulation, route, population and controls that were evaluated. It cannot verify the identity, amount, purity, sterility, stability or delivery of a separate vial. Those are batch-specific product questions, not automatic extensions of an efficacy result.
Is Semaglutide authorised in the UK for this use?
Semaglutide medicines are authorised in the UK for specific indications, strengths and populations. The authorisation applies to the named product and label, not to unlicensed powders or vials. The boundary matters because evidence, authorisation and product quality answer different questions and should not be merged into one conclusion.
What should competitive athletes know?
Semaglutide is not listed as a prohibited substance on the 2026 WADA Prohibited List, but athletes remain responsible for checking current rules and medicine documentation. The boundary matters because evidence, authorisation and product quality answer different questions and should not be merged into one conclusion.
What could change this verdict?
Major new head-to-head trials, material regulator safety changes, label changes or evidence that alters long-term benefit-risk in the authorised population. Any update would be dated and recorded through the site correction and version process. The boundary matters because evidence, authorisation and product quality answer different questions and should not be merged into one conclusion.
Continue the investigation